Amsterdam Institute for Molecular and Life Sciences (AIMMS), Division of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit, De Boelelaan 1108, Amsterdam 1081 HZ, The Netherlands.
OncoProteomics Laboratory, Department of Medical Oncology, Amsterdam University Medical Center (VUmc), 1081 HV Amsterdam, The Netherlands.
ACS Chem Biol. 2022 Nov 18;17(11):2972-2978. doi: 10.1021/acschembio.2c00299. Epub 2022 Oct 18.
The cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein found overexpressed in many types of cancer. CIP2A has been shown to stabilize oncoproteins such as cMYC by shielding them from PP2A-mediated dephosphorylation. Here we report that the penultimate residue Ser904 in the C-terminus of CIP2A can be phosphorylated to create a binding site for the regulatory protein 14-3-3. We demonstrate that 14-3-3 is a new interaction partner of CIP2A. The 14-3-3/CIP2A C-terminal interaction complex can be targeted by the protein-protein interaction (PPI) stabilizer fusicoccin-A (FC-A), resulting in enhanced levels of phosphorylated Ser904. FC-A treatment of TNBC cells leads to the increased association of CIP2A with 14-3-3. We show that the composite interface between 14 and 3-3 and CIP2A's C-terminus can be targeted by the PPI stabilizer FC-A, providing a new interface that could potentially be exploited to modulate CIP2A's activity.
致癌的蛋白磷酸酶 2A 抑制剂(CIP2A)是一种在许多类型的癌症中过表达的癌蛋白。已经表明,CIP2A 通过屏蔽它们免受 PP2A 介导的去磷酸化作用来稳定癌蛋白,如 cMYC。在这里,我们报告 CIP2A 羧基末端倒数第二个残基丝氨酸 904 可以被磷酸化,从而为调节蛋白 14-3-3 创建一个结合位点。我们证明 14-3-3 是 CIP2A 的一个新的相互作用伙伴。14-3-3/CIP2A 羧基末端相互作用复合物可以被蛋白-蛋白相互作用(PPI)稳定剂 fusicoccin-A(FC-A)靶向,导致磷酸化丝氨酸 904 水平升高。FC-A 处理三阴性乳腺癌(TNBC)细胞导致 CIP2A 与 14-3-3 的结合增加。我们表明,14-3-3 和 3-3 与 CIP2A 的羧基末端之间的复合界面可以被 PPI 稳定剂 FC-A 靶向,提供一个新的潜在可用于调节 CIP2A 活性的界面。